E242- (CME) Past, Present, and Future: Muscarinic-Targeting Treatments for Schizophrenia
NEI Podcast
00:00
Innovative Insights into Schizophrenia Treatments
This chapter explores the connections between cognitive deficits and negative symptoms in schizophrenia, focusing on new treatment avenues such as xenomaline trospium and amraclodine. It discusses the implications of neurotransmitter interactions, particularly glutamate and dopamine, on treatment efficacy, as well as the promising results from current phase two trials. The chapter emphasizes the need for tailored treatments that minimize cognitive impairments while effectively targeting both positive and negative symptoms.
Transcript
Play full episode
